Hydromorphone intrathecal - CNS Therapeutics

Drug Profile

Hydromorphone intrathecal - CNS Therapeutics

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CNS Therapeutics
  • Developer Piramal Enterprises
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pain

Most Recent Events

  • 20 Mar 2017 Mallinckrodt sold its Intrathecal Therapy Business of drugs for spasticity and pain management to Piramal Enterprises
  • 17 Feb 2016 Hydromorphone is still in phase III clinical trials for Pain in USA (Intrathecal)
  • 01 Jun 2013 CNS Therapeutics initiates enrolment in a phase III trial for Pain in USA (NCT01709747)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top